A1c Below ADA Target in Six Months: New Nourish Data Shows the Impact of Dietitian-Led Care on Blood Sugar for Adults with Diabetes
Real-world study presented at ObesityWeek, the world’s largest conference on obesity, found improvements in blood sugar
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Nourish, the country’s largest dietitian-led metabolic health clinic, presented results from a new real-world study this week at ObesityWeek, the premier conference focused on obesity research, treatment, prevention, and public policy. Among more than 2,000 adults with type 2 diabetes who stayed engaged in Nourish care for six months, working with a registered dietitian was associated with a clinically meaningful improvement in blood sugar.
Key findings
- 1.37 point A1c reduction: Steady improvement in A1c yielded a 1.15 point reduction after three months, and an average total reduction of 1.37 points after six months
- Improvement in adults not on GLP-1s: Results from this study were observed across medication profiles, including among adults with no GLP-1 exposure
To put that 1.37-point reduction in context, existing literature suggests that each percentage-point of improved A1c is associated with a 21% lower relative risk of diabetes-related complications, and a 37% lower relative risk of microvascular disease. These numbers are encouraging, given that type 2 diabetes affects around 1 in 10 U.S. adults and is a leading driver of preventable morbidity in this country.
While medical nutrition therapy is a recommended part of the management of type 2 diabetes, real-world evidence on outcomes from virtual care models remains limited. These results suggest that dietitian-led care contributes to improvements in blood sugar beyond concurrent medication use.
The retrospective analysis presented by the Nourish clinical research team included adults with type 2 diabetes who had at least one follow-up A1c measurement, and remained engaged in care over the course of six months (n=2,444). At Nourish, a registered dietitian serves as the entry point to care for all patients, with AI-powered support between visits.
“While GLP-1s have captured much of the attention in diabetes care, effective treatment goes well beyond any single medication,” said Nourish CMO Dr. Ajay Haryani. “Regardless of a patient’s medication regimen, consistent, longitudinal support from a Registered Dietitian is essential to improving glycemic control and sustaining those improvements over time. Our data showed that more than half of patients who started above the ADA’s glycemic target achieved that target within six months. It’s a powerful case for making nutrition care a foundational part of diabetes treatment for every patient.”
For more detail, see the poster here.
About Nourish
Nourish is the country’s largest dietitian-led metabolic health clinic, building the first AI-native virtual care model to tackle America’s healthcare crisis and reverse chronic disease. The company pairs 10,000+ Registered Dietitians with AI agents to deliver insurance-covered, personalized care that produces best-in-class outcomes. For patients who need access, Nourish integrates GLP-1 medication management, lab testing, and medical care into one care model designed for sustained behavior change. Through partnerships with the nation’s largest health plans, health systems, and employers, Nourish is available to over 200 million Americans across all 50 states, typically at no cost. Learn more at https://www.nourish.com/.
About ObesityWeek
The Obesity Society’s annual meeting brings together cutting-edge basic and clinical research, state-of-the-art treatment and prevention strategies, the latest advances in advocacy and public policy, real-world insights, and meaningful collaboration to move the field forward. Because obesity is a complex chronic disease, effective treatment requires a multidisciplinary approach. ObesityWeek brings together the full spectrum of obesity science—from basic research to translational studies and clinical application, to policy and population health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117649573/en/
Media gallery
